Trial Profile
Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer (ICONIC Trial)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 May 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Docetaxel; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ICONIC
- Sponsors Merck & Co
- 19 Apr 2023 Results of exploratory analysis(n=23) assessing whether ctDNA can predict recurrence and determine the efficacy of 4xFLOT+avelumab before and after surgery presented at the 114th Annual Meeting of the American Association for Cancer Research
- 14 Apr 2023 Results published in the Natera, Inc. Media Release
- 14 Apr 2023 According to Natera, Inc. media release, data from this study will be presented at the annual meeting of the American Association for Cancer Research (AACR)